BR0311696A - Tratamento de hepatite c na população asiática com interferon-beta subcutâneo - Google Patents

Tratamento de hepatite c na população asiática com interferon-beta subcutâneo

Info

Publication number
BR0311696A
BR0311696A BR0311696-4A BR0311696A BR0311696A BR 0311696 A BR0311696 A BR 0311696A BR 0311696 A BR0311696 A BR 0311696A BR 0311696 A BR0311696 A BR 0311696A
Authority
BR
Brazil
Prior art keywords
treatment
hepatitis
beta
subcutaneous
interferon beta
Prior art date
Application number
BR0311696-4A
Other languages
English (en)
Inventor
Ian Parsons
Theodor Wee Tit Gin
Birgit Maschek
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0311696A publication Critical patent/BR0311696A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"TRATAMENTO DE HEPATITE C NA POPULAçãO ASIáTICA COM INTERFERON-BETA SUBCUTâNEO". A invenção refere-se uso de IFN-beta recombinante para a produção de um medicamento para o tratamento de infecção de HCV através de administração subcutânea para pacientes de raça asiática, que falharam em responder a um prévio tratamento com interferon alfa, é aqui reportado. De acordo com uma modalidade preferida da invenção, este tratamento pode ser melhor e ainda focalizado para aqueles pacientes, que após 4 semanas de tratamento inicial com IFN-beta mostram limpeza de RNA HCV.
BR0311696-4A 2002-06-03 2003-05-28 Tratamento de hepatite c na população asiática com interferon-beta subcutâneo BR0311696A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100632 2002-06-03
PCT/EP2003/050202 WO2003101478A1 (en) 2002-06-03 2003-05-28 Treatment of hepatitis c in the asian population with subcutaneous interferonbeta

Publications (1)

Publication Number Publication Date
BR0311696A true BR0311696A (pt) 2005-03-22

Family

ID=29595047

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311696-4A BR0311696A (pt) 2002-06-03 2003-05-28 Tratamento de hepatite c na população asiática com interferon-beta subcutâneo

Country Status (21)

Country Link
US (1) US7344709B2 (pt)
EP (1) EP1509242A1 (pt)
JP (1) JP2005533035A (pt)
KR (1) KR20050008762A (pt)
CN (1) CN1671408A (pt)
AR (1) AR039915A1 (pt)
AU (1) AU2003250231B2 (pt)
BR (1) BR0311696A (pt)
CA (1) CA2487299A1 (pt)
EA (1) EA007091B1 (pt)
HR (1) HRP20041076A2 (pt)
IL (1) IL165521A (pt)
MX (1) MXPA04012043A (pt)
MY (1) MY139068A (pt)
NO (1) NO20045579L (pt)
PL (1) PL374578A1 (pt)
RS (1) RS105104A (pt)
TW (1) TWI334785B (pt)
UA (1) UA79615C2 (pt)
WO (1) WO2003101478A1 (pt)
ZA (1) ZA200409218B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
JP5359883B2 (ja) * 2007-11-28 2013-12-04 東レ株式会社 肝炎の治療剤又は予防剤
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
CN102538594B (zh) * 2012-01-10 2013-12-25 西安工业大学 交汇式激光精度靶及其测试方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
SK286654B6 (sk) 1998-04-28 2009-03-05 Laboratoires Serono Sa Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom

Also Published As

Publication number Publication date
HRP20041076A2 (en) 2005-02-28
EP1509242A1 (en) 2005-03-02
NO20045579L (no) 2005-01-26
ZA200409218B (en) 2006-02-22
WO2003101478A1 (en) 2003-12-11
CN1671408A (zh) 2005-09-21
KR20050008762A (ko) 2005-01-21
TWI334785B (en) 2010-12-21
US20060029572A1 (en) 2006-02-09
MXPA04012043A (es) 2005-03-07
IL165521A (en) 2010-05-17
AU2003250231B2 (en) 2009-01-08
JP2005533035A (ja) 2005-11-04
MY139068A (en) 2009-08-28
EA007091B1 (ru) 2006-06-30
PL374578A1 (en) 2005-10-31
UA79615C2 (en) 2007-07-10
AU2003250231A1 (en) 2003-12-19
TW200407159A (en) 2004-05-16
CA2487299A1 (en) 2003-12-11
IL165521A0 (en) 2006-01-15
RS105104A (en) 2007-02-05
US7344709B2 (en) 2008-03-18
EA200401618A1 (ru) 2005-06-30
AR039915A1 (es) 2005-03-09

Similar Documents

Publication Publication Date Title
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
AR023541A1 (es) Terapia de combinacion para vhc
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
BR0311696A (pt) Tratamento de hepatite c na população asiática com interferon-beta subcutâneo
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0108997A (pt) Terapia imune adjuvante para hiv
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
BR9915644A (pt) Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
BR9911774A (pt) Uso de interferon alfa 5 no tratamento das hepatopatias virais
Vrolijk et al. The treatment of hepatitis C: history, presence and future
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
UY28954A1 (es) Tratamiento de la miocardiopatía y la disfunción endotelial
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
NZ587372A (en) Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
TH70235A (th) วิธีการสำหรับการบำบัดรักษาการติดเชื้อไวรัสตับอักเสบ ซีในผู้ป่วยที่การบำบัดรักษาล้มเหลว
Kaiser et al. Long-term low dose treatment with pegylated interferon alpha 2b leads to a significant reduction in fibrosis and inflammatory score in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.